External validation of the SAVED score for venous thromboembolism risk stratification in patients with multiple myeloma receiving immunomodulatory drugs
Open Access
- 5 January 2023
- journal article
- research article
- Published by Wiley in British Journal of Haematology
- Vol. 201 (2) , 280-284
Abstract
Summary: Selective patients with multiple myeloma (MM) receiving immunomodulatory drugs (IMiD) are at high risk for venous thromboembolism (VTE). The SAVED score is a VTE risk prediction model recently incorporated into the National Comprehensive Cancer Network (NCCN) guidelines. Using retrospective data from 501 MM patients with new IMiD initiation between 2010 and 2019, we performed the first independent external validation of this model. The cumulative incidence of VTE after IMiD initiation at 6 and 12 months was 32% and 42% in the high‐risk group, versus 6% and 9% in the low‐risk group respectively. The C‐statistic of the SAVED score to predict VTE within 12 months of IMiD‐based treatment start was 0.74 [95% confidence interval (CI): 0.69–0.78], which outperformed several other VTE risk models in MM patients. Our findings suggest that the SAVED score is an accurate risk assessment tool for VTE stratification in patients initiating IMiD‐containing regimens.Keywords
This publication has 15 references indexed in Scilit:
- Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with CancerNew England Journal of Medicine, 2019
- Apixaban to Prevent Venous Thromboembolism in Patients with CancerNew England Journal of Medicine, 2019
- International Myeloma Working Group Consensus Statement for the Management, Treatment, and Supportive Care of Patients With Myeloma Not Eligible for Standard Autologous Stem-Cell TransplantationJournal of Clinical Oncology, 2014
- Venous Thromboembolism Risk in Patients With Cancer Receiving Chemotherapy: A Real-World AnalysisThe Oncologist, 2013
- Semuloparin for Thromboprophylaxis in Patients Receiving Chemotherapy for CancerNew England Journal of Medicine, 2012
- Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomideBlood, 2012
- Aspirin, Warfarin, or Enoxaparin Thromboprophylaxis in Patients With Multiple Myeloma Treated With Thalidomide: A Phase III, Open-Label, Randomized TrialJournal of Clinical Oncology, 2011
- Prevention of thalidomide- and lenalidomide-associated thrombosis in myelomaLeukemia, 2007
- Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapyJournal of Thrombosis and Haemostasis, 2007
- Malignancies, Prothrombotic Mutations, and the Risk of Venous ThrombosisJAMA, 2005